Share the Video:

Being a Psychedelic Therapist

Norma Stevens

This session will explore important underlying assumptions of psychedelic assisted therapy and how they affect the role of the therapist. We will also discuss BEING a psychedelic therapist–how one enters the space with presence to facilitate the healing in another. The speaker will use her own experiences in psychedelic assisted therapy with research volunteers using MDMA, psilocybin and ketamine to illustrate key concepts.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Psychedelics as The Great Disrupters: Reconstructing the Future of Mental Healthcare

Dr. Ben Sessa will discuss similarities among MDMA, ketamine, and psilocybin in clinical settings, exploring their potential in treating trauma-based disorders and challenges in psychedelic medicalization.

Ben Sessa

PS2023 MDMA MDMA-AT Policy and Advocacy Psychedelic Assisted Therapy PTSD Research

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.

Keren Tzarfaty, Michael Mithoefer, Julie Holland

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science Resources for Therapists

The State of Psychedelic Research Since 2017

Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.

Paul Summergrad, Tom Insel, Rachel Nuwer

PS2023 Depression Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

How do psychedelics work?

Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor

PS2023 DMT LSD MDMA Psilocybin Psychedelic Science Research

A conversation with Amanda Feilding and Rick Doblin, Ph.D.

Amanda Feilding, Founder of the Beckley Foundation, drives the Psychedelic Renaissance with groundbreaking research programs at top institutions worldwide, including pioneering studies on psilocybin, LSD, MDMA, and DMT.

PS2023 Integration Psychedelic Assisted Therapy Psychedelic Science Research Resources for Therapists

The Legacy of Stanislav Grof

Stanislav Grof, a pioneer in psychedelic research, presents the Grof® Legacy Training on 'holotropic' states of consciousness, with colleagues from international psychedelic training programs.

Brigitte Grof, Stanislav Grof, Diane Haug, Javier Charme, Neil Hannon, Jay Dufrechou

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023 MDMA Psychedelic Assisted Therapy Psychedelic Science Research

Grounding Psychedelic Research in Memory for Advancing Psychedelic Drug Discovery

M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.

James Keim

PS2023 Health Conditions Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research Therapy Ethics

Family Matters in Psychedelic Therapy: Lessons Learned from a Psilocybin Trial for Anorexia Nervosa

Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.

Jennifer Danby

Being a Psychedelic Therapist

Become a MAPS Member with a monthly donation

Related Videos